Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Inks Deal with WARF to Develop hESCs for Research Applications

NEW YORK (GenomeWeb News) - Invitrogen said today that it has licensed intellectual property from the Wisconsin Alumni Research Foundation that will enable it to develop research tools using human embryonic stem cells.
 
Under the terms of the agreement, the licensing organization for the University of Wisconsin-Madison has granted Invitrogen the right to work with karyotypically normal hESCs to develop research and drug discovery tools.
 
Joydeep Goswami, vice president of stem cells and regenerative medicine at Invitrogen, said in a statement that the agreement will enable Invitrogen to develop research tools "such as more defined media and engineered stem cell lines."
 
WARF said that it has now completed 24 licensing agreements for stem cell technologies with 18 companies.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.